deaths (OS)

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 certainty unassessable+44%
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-14%